Kenvue Inc. (NYSE:KVUE) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Kenvue Inc. (NYSE:KVUE) have received an average rating of “Hold” from the sixteen analysts that are covering the company, Marketbeat reports. Thirteen analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $19.5833.

A number of equities research analysts have issued reports on the stock. Wall Street Zen raised shares of Kenvue to a “buy” rating in a research report on Sunday, July 12th. Barclays boosted their target price on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 21st. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Zacks Research lowered Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, Citigroup decreased their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, April 15th.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $19.77 on Thursday. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67. The stock’s fifty day simple moving average is $18.52 and its two-hundred day simple moving average is $17.98. Kenvue has a 1-year low of $14.02 and a 1-year high of $22.35. The stock has a market cap of $37.97 billion, a PE ratio of 23.26, a price-to-earnings-growth ratio of 1.50 and a beta of 0.47.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. The firm had revenue of $3.91 billion during the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The business’s revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.24 EPS. As a group, analysts forecast that Kenvue will post 1.16 EPS for the current fiscal year.

Kenvue Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th will be issued a $0.21 dividend. This is a boost from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Wednesday, August 12th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 4.2%. Kenvue’s payout ratio is presently 97.65%.

Insider Buying and Selling

In related news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 1.59% of the company’s stock.

Institutional Trading of Kenvue

Several hedge funds have recently made changes to their positions in the company. Norges Bank bought a new position in shares of Kenvue during the 4th quarter worth $756,862,000. Independent Franchise Partners LLP raised its stake in Kenvue by 56.3% in the 4th quarter. Independent Franchise Partners LLP now owns 48,146,476 shares of the company’s stock valued at $830,527,000 after acquiring an additional 17,343,785 shares during the period. Sculptor Capital LP raised its stake in Kenvue by 1,023.5% in the 4th quarter. Sculptor Capital LP now owns 12,886,328 shares of the company’s stock valued at $222,289,000 after acquiring an additional 11,739,328 shares during the period. Capitolis Liquid Global Markets LLC lifted its holdings in Kenvue by 1,116.8% during the fourth quarter. Capitolis Liquid Global Markets LLC now owns 10,950,999 shares of the company’s stock valued at $188,905,000 after purchasing an additional 10,050,999 shares during the last quarter. Finally, Cibc World Markets Corp bought a new position in Kenvue during the fourth quarter worth about $162,193,000. 97.64% of the stock is currently owned by institutional investors.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.